


Appl. No. 10/030,735
 Amdt. dated November 11, 2005
 Amendment and Reply under 37 CFR 1.116 Expedited
 Procedure Examining Group 1644

PATENT

Amendments to the Specification:

Please replace the paragraph on page 16, beginning on line 22, with the following amended paragraph:

The present invention generally provides peptides, comprising the sequence



wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; the ~~X₁-X₂-X₃-X₄ sequence is selected from the group consisting of~~

~~N V R V, N V R I, N V R L, N V R F (SEQ ID NOS: 55-57 & 51),
 N V K V, N V K I, N V K L, N V K F (SEQ ID NOS: 58-61),
 N I R V, N I R I, N I R L, N I R F (SEQ ID NOS: 62-65),
 N I K V, N I K I, N I K L, N I K F (SEQ ID NOS: 66-69),
 N L R V, N L R I, N L R L, N L R F (SEQ ID NOS: 70-73),
 N L K V, N L K I, N L K L, N L K F (SEQ ID NOS: 74-77),
 Q V R V, Q V R I, Q V R L, Q V R F (SEQ ID NOS: 78-80 & 53),
 Q V K V, Q V K I, Q V K L, Q V K F (SEQ ID NOS: 81-83),
 Q I R V, Q I R I, Q I R L, Q I R F (SEQ ID NOS: 84-87),
 Q I K V, Q I K I, Q I K L, Q I K F (SEQ ID NOS: 88-91),
 Q L R V, Q L R I, Q L R L, Q L R F (SEQ ID NOS: 92-95),
 Q L K V, Q L K I, Q L K L, Q L K F (SEQ ID NOS: 96-99),
 D V R V, D V R I, D V R L, D V R F (SEQ ID NOS: 100-102 & 54),
 D V K V, D V K I, D V K L, D V K F (SEQ ID NOS: 103-106),~~

Appl. No. 10/030,735

PATENT

Amdt. dated November 11, 2005

Amendment and Reply under 37 CFR 1.116 Expedited

Procedure Examining Group 1644

~~D-I-R-V, D-I-R-I, D-I-R-L, D-I-R-F (SEQ ID NOS: 107-110),~~
~~D-I-K-V, D-I-K-I, D-I-K-L, D-I-K-F (SEQ ID NOS: 111-114),~~
~~D-L-R-V, D-L-R-I, D-L-R-L, D-L-R-F (SEQ ID NOS: 115-118),~~
~~D-L-K-V, D-L-K-I, D-L-K-L, D-L-K-F (SEQ ID NOS: 119-122),~~
~~S-V-R-V, S-V-R-I, S-V-R-L, S-V-R-F (SEQ ID NOS: 123-125 & 52),~~
~~S-V-K-V, S-V-K-I, S-V-K-L, S-V-K-F (SEQ ID NOS: 126-129),~~
~~S-I-R-V, S-I-R-I, S-I-R-L, S-I-R-F (SEQ ID NOS: 130-133),~~
~~S-I-K-V, S-I-K-I, S-I-K-L, S-I-K-F (SEQ ID NOS: 134-137),~~
~~S-L-R-V, S-L-R-I, S-L-R-L, S-L-R-F (SEQ ID NOS: 138-141),~~
~~S-L-K-V, S-L-K-I, S-L-K-L, S-L-K-F (SEQ ID NOS: 142-145),~~

R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. In one embodiment of the invention, peptides having the sequence FQGV LQNVR FVF (SEQ ID NO:6) or FRGCVRNLRLSR (SEQ ID NO:12) are specifically excluded. In one embodiment, the peptides contain from 4 to 12 amino acids, i.e., has a length of 4 to 12 amino acid residues. In one embodiment, the peptides comprise additional residues, e.g., typically up to a length of 15, 20, 25, or 40 residues that includes the core sequence (I).